Speakers:
Organizers: Toby Freedman, Joseph Carlino, Shichang Miao, Snow Ge, Wenfeng Xu, Donald McCarthy and Betty Chang
Date: 2021-08-11- 08/12/2021
Time: 8:30-13:00 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-08-09  (it will close sooner if the seating cap is reached)

About the Topic

The last few years has seen major advancements in cancer treatment through immunotherapy. This symposium aims to provide a comprehensive overview of the emerging concepts in cancer immunotherapy from the latest biologic insights in academia and the latest clinical data for approved and investigational immuno-oncology agents from key biotech and pharmaceutical companies. We will discuss the latest partnership trends and business development efforts in this rapidly evolving landscape. 

Tentative Agenda:

Day 1, Wednesday, August 11, 2021 (Pacific Time)

8:30 AM - 8:45 AM          Welcome Remarks  (Shichang Miao, President of PBSS & Joseph Carlino, President of BioScience Forum)

8:45 AM - 9:20 AM          Targeting MYC Oncogene Pathway: Global Gatekeeper of Tumor Growth and Immune Evasion (Dean Felsher, Professor, Stanford Medical School)

9:20 AM - 9:55 AM          Engineering IL-12 for Localized Tumoral Activity (Jeff Hubbell, Scientific Founder, Arrow Immune)

9:55 AM - 10:30 AM        Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment (Elsa Quintana, Director and Head of Immuno-Oncology, Revolution Medicines)

10:30 AM - 10:50 AM     BREAK  

10:50 AM - 11:25 AM     A novel platform for localized intratumoral expression of immunotherapy: GET IT (Bridget O'Keeffe, VP - Clinical Development, OncoSec)

11:25 AM - 12:00 PM      Tumor-targeting immune stimulating antibody conjugates (David Dornan, Chief Scientific Officer, Bolt Biotherapeutics)

12:00 PM - 12:35 PM      Considerations in design of T-cell bispecifics and translational PKPD approaches: A case study in CRC (Vittal Shivva, Principal Scientist, Genentech)

12:35 PM - 1:10 PM        How does PD-1 immunotherapy work -- mechanistic insights from recent studies? (Adil Daud, Professor, UCSF)

1:10 PM - 1:40 PM           Panel Discussion (All speakers; Moderated by Donald McCarthy of PBSS)                                

Day 2, Thursday, August 12, 2021 (Pacific Time)                               

8:30 AM - 8:35 AM          Welcome Remarks  (Toby Freedman, BioScience Forum)

8:35 AM - 9:10 AM          IL1RAP as a target for antibody therapy in oncology and inflammation (Goran Forsberg, CEO, Cantargia)

9:10 AM - 9:45 AM          Elucidating the anti-cancer activity of adenosine inhibition: A2R blockade (etrumadenant) and CD73 inhibition (AB680) in clinical trials (Juan Jaen, President/Head of R&D, Arcus BioSciences)

9:45 AM - 10:20 AM        Novel Myeloid Checkpoint Inhibitors as Next Generation of Immune-Oncology Therapy (An Song, Chief Scientific Officer, Immune-Onc Therapeutics)

10:20 AM - 10:55 AM     Targeting HLA-G-Mediated Immunosuppression with a First-in-Class Antagonist Antibody (Courtney Beers, Chief Scientific Officer, Tizona Therapeutics)

10:55 AM - 11:05 AM     Break

11:05 AM - 11:40 AM     A survey of the PD-1 / PD-L1 small molecule inhibitors landscape (Penglie Zhang, VP - Chemistry, ChemoCentryx) 

11:40 AM - 12:15 PM     Addressing Relapse in Liquid Tumors: Reversing Antigen Escape with Bryostatin-1 (Sam Kongsamut, VP - Research, BryoLogyx)

12:15 PM - 12:50 PM     The Amazing Race of I/O Agents (Cheni Kwok, Linear Dreams & Ji Li, VP, Immune-Onc Therapeutics)

12:50 PM - 1:30 PM       Panel Discussion (All speakers; Moderated by Betty Chang & Wenfeng Xu of PBSS)